Literature DB >> 17142731

High accumulation of T regulatory cells prevents the activation of immune responses in aged animals.

Sanjay Sharma1, Ana Lucia Dominguez, Joseph Lustgarten.   

Abstract

In our previous in vivo study we demonstrated that young BALB/c mice effectively rejected the BM-185 tumor cells expressing enhanced GFP (EGFP) as a surrogate tumor Ag. In contrast, old BALB/c mice succumbed to the BM-185-EGFP tumors, indicating that there is a deficiency in old animals preventing the rejection of immunogenic tumors. There is cumulative evidence indicating that regulatory T (T(reg)) cells control the activation of primary and memory T cell responses. However, very little is known about whether there is a relation between T(regs) and the lack of immune responses in the aged. We evaluated young and aged animals, and our results demonstrated that there are significantly more CD4+CD25+FoxP3+ and CD8+CD25+FoxP3+ T(regs) in the spleen and lymph nodes of old animals when compared with the young. Depletion of CD25+ cells with anti-CD25 mAb induces the rejection of BM-185-EGFP cells, restores antitumor T cell cytotoxic activity, and results in the generation of a protective memory response against the BM-185 wild-type tumors in old mice. Furthermore, vaccination with CpG-oligodeoxynucleotide decreases the number of T(reg) cells in old animals to the same levels as young mice, restoring the primary and memory antitumor immune responses against BM-185-EGFP tumors. Taken together, these results indicate that there is a direct correlation between the expansion of T(reg) cells and immune deficiency in the old, and that depletion of these cells might be critical for restoring immune responses in aged animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142731     DOI: 10.4049/jimmunol.177.12.8348

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  99 in total

1.  Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue.

Authors:  Carey N Lumeng; Jianhua Liu; Lynn Geletka; Colin Delaney; Jennifer Delproposto; Anjali Desai; Kelsie Oatmen; Gabriel Martinez-Santibanez; Annabelle Julius; Sanjay Garg; Raymond L Yung
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

2.  A major role for Bim in regulatory T cell homeostasis.

Authors:  Claire A Chougnet; Pulak Tripathi; Celine S Lages; Jana Raynor; Allyson Sholl; Pamela Fink; David R Plas; David A Hildeman
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

3.  Effects of aging and dietary restriction on ubiquitination, sumoylation, and the proteasome in the spleen.

Authors:  Le Zhang; Feng Li; Edgardo Dimayuga; Jeffrey Craddock; Jeffrey N Keller
Journal:  FEBS Lett       Date:  2007-11-06       Impact factor: 4.124

Review 4.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 5.  [Oncoimmunology in old age].

Authors:  M C Wigand; S Jeske; J Hahn; J Doescher; S Laban; T K Hoffmann; P J Schuler
Journal:  HNO       Date:  2020-03       Impact factor: 1.284

Review 6.  Immune senescence, epigenetics and autoimmunity.

Authors:  Donna Ray; Raymond Yung
Journal:  Clin Immunol       Date:  2018-04-11       Impact factor: 3.969

Review 7.  Epigenetics, aging, and autoimmunity.

Authors:  Raymond L Yung; Annabelle Julius
Journal:  Autoimmunity       Date:  2008-05       Impact factor: 2.815

Review 8.  Immunosenescence and immune response in organ transplantation.

Authors:  Paulo Ney Aguiar Martins; Stefan G Tullius; James F Markmann
Journal:  Int Rev Immunol       Date:  2013-10-15       Impact factor: 5.311

Review 9.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

10.  A grim picture, indeed.

Authors:  J Jason Hoth
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.